The Technical Analyst
Adagio Therapeutics, Inc. [ADGI]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Adagio Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.87% $4.64
/ 13 sep 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 505.68 mill |
| EPS: | -2.63 |
| P/E: | -1.762 |
| Earnings Date: | Sep 19, 2022 |
| SharesOutstanding: | 108.98 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2022-11-14 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | |||||
| Asset | n/a | |||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.762 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.762 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.28 - 5.00 ( +/- 7.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-09-01 | Hering David | Buy | 8 000 | Common Stock |
| 2022-08-17 | M28 Capital Management Lp | Buy | 584 451 | Common Stock |
| 2022-07-05 | Hering David | Buy | 2 000 000 | Stock Option (Right to Buy) |
| 2022-06-22 | Meanwell Clive | Buy | 150 000 | Stock Option (Right to Buy) |
| 2022-06-22 | Berry Tamsin | Buy | 150 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 73 transactions |
| Buy: 92 517 480 | Sell: 27 506 245 |
Forecast:
01:40 - $4.54
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.64 (0.87% ) |
| Volume | 0.535 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADGI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ADGI
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Latest Press Releases
2022-09-06 16:01:00 - Press Release
Adagio Therapeutics To Participate In Upcoming Investor Conferences
Waltham, mass., sept. 06, 2022 (globe newswire) -- adagio therapeutics, inc. (nasdaq: adgi), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences:
2022-01-06 06:30:00 - Press Release
Adagio Therapeutics To Present At The 40th Annual J.p. Morgan Healthcare Conference
Waltham, mass., jan. 06, 2022 (globe newswire) -- adagio therapeutics, inc., (nasdaq: adgi) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that tillman gerngross, ph.d., chief executive officer of adagio, is scheduled to present at the 40th annual j.p. morgan healthcare conference on thursday, january 13, 2022 at 7:30 a.m. et.
2021-11-10 06:30:00 - Press Release
Adagio Therapeutics To Participate In Upcoming Investor Conferences
Waltham, mass., nov. 10, 2021 (globe newswire) -- adagio therapeutics, inc., (nasdaq: adgi) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced participation in the following upcoming investor conferences:
2021-10-19 06:30:00 - Press Release
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad And Potent Neutralization Of Adg20 Against All Known Sars-cov-2 Variants
Data to be presented at the 2021 isirv-who virtual conference data to be presented at the 2021 isirv-who virtual conference
2021-09-29 06:30:00 - Press Release
Adagio Therapeutics Announces New Data Highlighting The Potential Of Adg20 For Treatment And Prevention Of Covid-19
Adg20 continues to be well tolerated in healthy volunteers with prolonged half-life and serum virus neutralization activity observed out to six months in ongoing phase 1 study
Latest News
2022-09-06 16:01:00 - GlobeNewsWire
Adagio Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences:
2022-08-22 20:08:58 - 24/7 Wall Street
Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%
Last Friday, health care focused hedge fund M28 Capital filed a 13D/A with the US Securities & Exchange Committee revealing it bought 2.85 million Adagio Therapeutics (US:ADGI) at an average of $4.28 per share, bringing its holding to 9.2 million, or 8.5% of the company.
2022-03-31 13:33:12 - Zacks Investment Research
Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.
2022-03-30 13:41:41 - InvestorPlace
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
2022-03-30 11:27:05 - Benzinga
Adagio's COVID-19 Antibody Meets Primary Goals Across Pre & Post-Exposure Prophylaxis, Treatment
Adagio Therapeutics Inc's (NASDAQ: ADGI) Phase 2/3 trials evaluating 300 mg adintrevimab (ADG20) as pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19 have met its primary endpoints. Following the emergence of the omicron variant, a pre-specified exploratory.
2022-03-30 10:50:50 - The Motley Fool
Why Adagio Therapeutics Stock Is Soaring Today
Investors are reacting to better than expected clinical trial results for its COVID-19 treatment candidate.
2022-03-30 10:23:02 - Benzinga
Why Adagio Therapeutics Stock Is Soaring Today
Adagio Therapeutics Inc (NASDAQ: ADGI) is trading higher Wednesday after the company announced its investigational drug adintrevimab (ADG20) was the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment.
2022-03-30 09:33:00 - Barrons
Adagio Stock Spikes on New Data, but Its Omicron Problems Remain
Adagio Therapeutics says it will seek an emergency use authorization for its Covid-19 antibody, known as ADG20, in the second quarter.
2022-03-30 09:30:27 - PennyStocks
Trading Penny Stocks? Top Stock Market News for March 30th, 2022
Here's what you need to know about trading penny stocks on March 30th The post Trading Penny Stocks? Top Stock Market News for March 30th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-03-23 17:32:00 - GuruFocus
2 Net Current Asset Value Stocks to Consider
There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe there is a lot to gain in these stocks after the market reprices shares to near or above their liquidation value.